Revenue segments as reported by the company.

Products

Premiums

Services

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefit costs

Operating expenses

Goodwill impairment

Store impairments

Opioid litigation charges

Loss on assets held for sale

Restructuring charge

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CVS Health

Aetna is an American managed health care company, which sells traditional and consumer directed health care insurance plans and related services, such as medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans. Aetna is a member of the Fortune 500.

Aetna

CVS Pharmacy is a subsidiary of the American retail and health care company CVS Health, headquartered in Woonsocket, Rhode Island. It was also known as, and originally named the Consumer Value Store and was founded in Lowell, Massachusetts, in 1963. The chain was owned by its original holding company Melville Corporation since its inception until its current parent company CVS Health was spun off into its own company in 1996. CVS Pharmacy is currently the largest pharmacy chain in the United States by number of locations (over 9,600 as of 2016) and total prescription revenue. As the retail pharmacy division of CVS Health, it ranks as the 7th largest U.S. corporation according to Fortune 500 in 2016. CVS Pharmacy's leading competitor Walgreens Boots Alliance ranked 37th.

CVS Pharmacy

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CVS Health exceeds Q4 expectations, eyes growth with Oak Street

CVS Health's strong financial performance in 2022, driven by revenue growth and exceeding EPS expectations, positions the company well for future growth.
The acquisition of Oak Street Health presents opportunities to expand into primary care and improve long-term earnings growth, despite challenges in maintaining retail performance.

CVS Health excels in Q1, eyes growth through acquisitions and innovation

CVS Health's strong financial performance, strategic acquisitions, and customer-centric initiatives position the company for sustained growth and competitive advantage.
While facing challenges in the evolving healthcare landscape, CVS Health's focus on innovation, affordability, and operational efficiency provides a solid foundation for future success.
By capitalizing on opportunities in growth, synergies, and healthcare services, CVS Health can navigate industry headwinds and drive long-term value creation for stakeholders.

CVS Health reports robust Q2 earnings, eyes growth opportunities

CVS Health's Q2 2023 performance reflects strong financial results and strategic acquisitions driving growth.
Despite challenges like higher costs and restructuring charges, the company remains confident in its ability to deliver outstanding performance.
Opportunities lie in expanding Medicaid contracts, biosimilar market establishment, and clinic openings for at-risk populations.
Overall, CVS Health's focus on cost optimization, digital sales growth, and patient engagement positions it well for future success.

CVS Health reports robust Q3 earnings and strategic growth plans

CVS Health's Q3 performance reflects strong financial results and strategic initiatives across its segments, positioning the company for sustainable growth.
While facing challenges like declining vaccine demand and contract losses, CVS Health is focused on leveraging opportunities in biosimilars and cost-saving solutions.
The company's commitment to operational excellence, innovation, and workforce investment underscores its strategic vision for becoming a leading health solutions provider.
With a clear focus on growth drivers and mitigating challenges, CVS Health is poised to capitalize on market opportunities and deliver value to shareholders.

CVS Health reports robust Q4 earnings, eyes Medicare margin recovery

CVS Health's Q4 2023 earnings call highlighted strong financial performance, a cautious stance on Medicare Advantage utilization, and a focus on transforming healthcare delivery. The company is committed to margin recovery, growth, and enhancing customer experience while addressing challenges in Medicare Advantage trends and cost pressures.

CVS Health faces Medicare Advantage challenges, focuses on margin improvement

CVS Health's Q1 2024 earnings call highlighted strong financial performance, challenges in the Medicare Advantage business, and a focus on improving margins. The company showcased strengths in the biosimilar market and Pharmacy & Consumer Wellness segment while addressing issues impacting Health Care Benefits and Services segments.

CVS Health's Q2 2024 performance reflects strong financial results, cost savings, and innovative initiatives in pharmacy services.
The company faces challenges in the Health Care Benefits segment but is actively addressing them through leadership changes and operational improvements.
Opportunities for growth include driving margin improvements, expanding digital reach, and educating stakeholders on the value delivery of PBMs.
Expectation of margin recovery in Medicare Advantage and double-digit EPS growth in 2025 highlight CVS Health's strategic focus on operational efficiencies and cost savings.

CVS Health reports robust Q3 earnings, focuses on growth strategies

CVS Health's Q3 2024 performance was marked by strong financial results, leadership changes, and segment-specific challenges and successes. The company is focused on leveraging opportunities in strategic initiatives and addressing areas for improvement to drive future growth.

Revenue

Cost of revenue

Gross profit

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WOONSOCKET, R.I. , July 20, 2023 /PRNewswire/ -- CVS Health® Corporation (NYSE: CVS) has appointed J.

CVS Health appoints Scott Kirby to Board of Directors

Tandem Diabetes Care

CVS Health's broad array of healthcare services makes it an excellent long-term pick. Tandem Diabetes Care can still benefit from the vast untapped market within its niche.

2 Health Stocks Down 23% or More This Year That Could Rebound

Herbalife

Rite Aid

The Zacks Retail Pharmacy and Drugstore industry players like CVS, HLF and RAD are likely to gain despite reimbursement challenges hurting the overall industry health.

3 Retail Pharmacy and Drugstore Stocks to Watch Amid Industry Headwinds

Recently, Zacks.com users have been paying close attention to CVS Health (CVS). This makes it worthwhile to examine what the stock has in store.

Is Most-Watched Stock CVS Health Corporation (CVS) Worth Betting on Now?

Lear

Phillips 66

A good tool for spotting turnaround candidates is the price-sales ratio.

CVS, Phillips 66 and Lear Look Good on This Gauge

CVS, originally a convenience store, is now a diversified health solutions company, operating in Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. Despite underperforming the broader stock market YTD, it now offers an attractive entry point and it is well-positioned to outperform in the next 12-18 months. CVS faces challenges such as e-commerce competition, legislative pressure on its PBM business, and high leverage, but its vertical integration with Aetna and potential for digital transformation could provide future growth.

CVS Health: A Portfolio Must Have

Analog Devices

American Financial Group

Ally Financial

American Tower

Amazon

Broadcom

Best Buy

Boston Omaha

Carrier Global

Cogent Communications Holdings

Comcast

Digital Realty Trust

Enterprise Products Partners

Essential Properties Realty Trust Inc

Fidelity National Financial

Corning

General Motors

Graphic Packaging Hld

Global Payments

Home Depot

Lockheed Martin

Altria

MPLX

Dividend income has grown by 35.77% in the first half of 2023, adding $1,606 to estimated annual dividends, due to dividend reinvestments, dividend increases, new purchases, and re-allocation of capital. Several changes have been made to the portfolio, including closing seven positions and reallocating capital to five new positions, aiming for a balanced approach to dividend growth for long-term sustainability. The goal is to reach $6,600 in estimated annual dividends by the end of the year.

My Dividend Growth Income Mid-Year Review

UnitedHealth Group

America's national health expenditure reached $4.3 trillion in 2021, and it's expected to continue rising by 5.4% annually through 2031. CVS Health is famous for pharmacies, but it also runs Aetna, a health insurance benefits management business.

2 Exceptional Dividend Growth Stocks to Buy Near 52-Week Lows

Apple

AbbVie

Arbor Realty Trust

Abbott Labs

Archer-Daniels-Midland Company

Aflac

Ameriprise Financial

American Express

Bank of America

Becton, Dickinson and Co.

Blackrock Inc

Bristol-Myers

Citigroup

Cardinal Health

Caterpillar

Cisco Systems

Chevron

Disney

Duke Energy

Emerson Electric

Eaton

In 2015, I started publishing updates regarding my dividend growth portfolio, and I keep doing so every quarter. This is part of being transparent with my readers, so they can see what I hold and its correlation with my writing. This article summarizes Q2 of 2023 and focuses on goals, current holdings, allocation, sales, and buys.

My Dividend Growth Portfolio - Q2 2023 Summary

CVS Health (CVS) is able to dynamically shop for the lowest price on its clients' behalf with the help of Caremark Cost Saver solution.

CVS Health (CVS) Launches Caremark Cost Saver With a New Pact

CRISPR Therapeutics

CRISPR Therapeutics could soon have an approved gene-editing therapy it can price at over $1 million. CVS Health's expanding business makes it a relatively safe investment with tons of growth potential.

2 No-Brainer Healthcare Stocks to Buy With $100 Right Now

CVS Health, a vertically-integrated healthcare giant, is currently undervalued despite growing revenues and recent acquisitions, making it a potential bargain for value investors. CVS's acquisition of Oak Street Health, a Medicare-focused primary care company, is expected to bring synergistic savings and contribute to potential EBITDA, despite initial losses.

CVS Health: Buy The Complexity Discount

GoodRx Holdings

GoodRx, a leading prescription discount platform, has announced a new partnership with CVS Health Corp (NYSE:CVS)'s Caremark, a major pharmacy benefits manager (PBM). The collaboration will introduce a new product called Caremark Cost Saver, which aims to help commercially insured customers save on generic drugs at eligible pharmacies.

GoodRx surges on partnership with CVS's Caremark to help customers save on prescription drugs

CVS Health's Caremark pharmacy benefit management (PBM) company and the drug discount app GoodRx are launching a service they hope will lower drug costs for commercial

CVS Health's PBM And GoodRx Partner On Drug Discount Program For Commercially Insured Customers

AstraZeneca

Medtronic

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

These 3 Health Care Stocks Delivering High-Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts - CVS Health (NYSE:CVS), AstraZeneca (NASDAQ:AZN)

GoodRx GDRX, -1.64% shares gained 3.5% premarket on Wednesday after the drug-savings app provider and CVS Health CVS, +2.75% announced a new program to lower out-of-pocket prescription drug costs for CVS Caremark clients' members. CVS Caremark eligible members will have automatic access to GoodRx prescription pricing, potentially generating savings on generic medications at the pharmacy counter, the companies said in a release Wednesday.

GoodRx shares gain on new prescription-drug discount program with CVS

Prescription drug discount solution to help lower costs, improve experience for tens of millions of CVS Caremark clients' members WOONSOCKET, R.I., and SANTA MONICA, Calif.

CVS Caremark and GoodRx to launch Caremark® Cost Saver™ to help lower out-of-pocket drug costs for CVS Caremark clients' members

CVS Health Corp.'s CVS, +2.75% Caremark prescription drug-benefits manager spent Tuesday trying to return to normal following delays that began on Monday, according to the Wall Street Journal late Tuesday. CVS sent letters to pharmacies nationwide warning of an “unexpected system slowdown,” and that operations were back to normal, the Journal reported.

CVS resolving ‘unexpected system slowdown' delaying prescriptions: WSJ

News for CVS Health Stock (CVS)